


FORM PTO-1390 (REV 11-98)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 159-64
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <b>09/786815</b> Unknown	
INTERNATIONAL APPLICATION NO. <b>PCT/JP00/04651</b>	INTERNATIONAL FILING DATE <b>12 July 2000</b>	PRIORITY DATE CLAIMED <b>12 July 1999</b>	
TITLE OF INVENTION <b>PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION</b>			
APPLICANT(S) FOR DO/EO/US <b>TATAR et al.</b>			
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li>4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19<sup>th</sup> month from the earliest claimed priority date.</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)). <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul> </li> <li>6. <input checked="" type="checkbox"/> A translation of the International Application and Request into English (35 U.S.C. 371(c)(2)).</li> <li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> have been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has <b>NOT</b> expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ul> </li> <li>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (U.S.C. 371(c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>			
<p><b>Items 11. To 16. Below concern document(s) or information included:</b></p> <ol style="list-style-type: none"> <li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.</li> <li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.</li> <li>13. <input type="checkbox"/> A FIRST preliminary amendment.</li> <li>14. <input type="checkbox"/> A SUBSTITUTE specification.</li> <li>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>16. <input checked="" type="checkbox"/> Other items or information. <b>PTO-1449 and copy of International Search Report</b>  <input type="checkbox"/> This application is entitled to "Small entity" status. <input type="checkbox"/> "Small entity" statement attached.</li> </ol>			

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) Unknown	INTERNATIONAL APPLICATION NO. PCT/JP00/04651	ATTORNEY'S DOCKET NUMBER 159-64			
17. <input checked="" type="checkbox"/> The following fees are submitted:		<b>CALCULATIONS</b> PTO USE ONLY			
<b>BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5):</b>					
-- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1000.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$860.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2) paid to USPTO ..... \$710.00 -- International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$690.00 -- International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>		\$ 860.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).		\$ 130.00			
<b>CLAIMS</b>		<b>NUMBER FILED</b>	<b>NUMBER EXTRA</b>	<b>RATE</b>	
Total Claims	19	-20 =	0	X \$18.00	\$ 0.00
Independent Claims	5	-3 =	2	X \$80.00	\$ 160.00
<b>MULTIPLE DEPENDENT CLAIMS(S) (if applicable)</b>				\$270.00	\$ 270.00
				<b>TOTAL OF ABOVE CALCULATIONS =</b>	\$ 1420.00
Reduction by 1/2 for filing by small entity, if applicable. Small entity status must also be asserted. (Note 37 C.F.R. 1.9, 1.27, 1.28).					0.00
				<b>SUBTOTAL =</b>	\$ 1420.00
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).					0.00
				<b>TOTAL NATIONAL FEE =</b>	\$ 1420.00
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property					0.00
Fee for Petition to Revive Unintentionally Abandoned Application (\$1240.00 - Small Entity = \$620.00)					0.00
				<b>TOTAL FEES ENCLOSED =</b>	\$ 1420.00
				Amount to be: refunded	\$
				Charged	\$
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$1420.00 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees. A duplicate copy of this form is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A <u>duplicate</u> copy of this form is enclosed.</p> <p>d. <input type="checkbox"/> The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application.</p>					
<b>NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
 <b>SEND ALL CORRESPONDENCE TO:</b> _____ <b>NIXON &amp; VANDERHYE P.C.</b> 1100 North Glebe Road, 8 <sup>th</sup> Floor Arlington, Virginia 22201 Telephone: (703) 816-4000					
<b>SIGNATURE</b> _____ <b>Arthur R. Crawford</b> NAME _____ <b>25,327</b> <b>March 9, 2001</b> REGISTRATION NUMBER Date _____					

VERIFICATION OF A TRANSLATION

I, the below named translator, hereby declare that:

My name and post office address are as stated below:

That I am knowledgeable in the English language and in the language in which the below identified application was filed, and that I believe the English translation of International Application No. PCT/JP00/04651 is a true and complete translation of the above identified International Application as filed.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dated this 5th day of March, 2001

Full name of the translator: Kiyoshi MURAKAMI

Signature of the translator:

Kiyoshi Murakami

Post Office Address: c/o YUASA AND HARA, Section 206,  
New Otemachi Bldg., 2-1,  
Otemachi 2-chome, Chiyoda-ku,  
Tokyo, JAPAN

4 | PRTS

09/786815

JC02 Rec'd PCT/PTO 09 MAR 2001

## SPECIFICATION

### PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION

#### TECHNICAL FIELD OF THE INVENTION

5       The present invention relates to a technique for topical administration of an active ingredient. More specifically, the invention relates to a pharmaceutical base which takes a soft gelled form suitable for administration before being applied topically, and which  
10      hardens after application and can hold an active ingredient topically for a long period; and a pharmaceutical composition for topical administration which has been prepared with the use of the base so as to achieve controlled release of a drug.

#### 15      PRIOR ART

Ointments, gels and creams, which can be administered easily and which are convenient in view of portability, are used as preparations for topical administration in various diseases. Ointments of antibiotics are useful particularly  
20      for topical inflammatory diseases due to infection with microorganisms, or pyogenic or infectious diseases. Therapeutic agents consisting of various antibiotics as an active ingredient have been demanded, and some of them find practical use.

25      As ointments consisting of various antibiotics as an active ingredient, for example, antibiotics, such as aminoglycosides, tetracyclines, and chloramphenicols, are frequently used in the treatment of inflammatory diseases

and pyogenic diseases in the fields of dermatology, ophthalmology, otorhinolaryngology, dentistry/oral surgery, urology, and gynecology. Concretely, an ointment of kanamycin sulfate, which is an aminoglycoside antibiotic,

5 an ointment of tetracycline hydrochloride, a tetracycline antibiotic, and an ointment of chloramphenicol, a chloramphenicol antibiotic, are commercially available as agents for treatment of pyogenic disease in dermatology.

An ophthalmic ointment of a pimaricin preparation, which  
10 is a macrolide antibiotic, is also on the market. An ointment containing tetracycline hydrochloride, which is a tetracycline antibiotic, and hydrocortisone acetate, is sold for dentistry and oral surgery.

An ointment requires that its active ingredient be  
15 stably incorporated into a pharmaceutical composition.

Japanese Patent Publication No. 12728/1989 describes that a pharmaceutical composition for topical administration, which has a magnesium compound incorporated into a hydrogel composed of a water-soluble polymer, a polyhydric alcohol  
20 and minocycline, one of tetracyclines, or its pharmaceutically acceptable salt, to stabilize the antibiotic, is used as a therapeutic agent administered topically for periodontal disease.

When an ointment is used as an intraoral preparation,  
25 for example, for treatment of periodontal disease, it is also necessary that its active ingredient be stable, and outflow of the active ingredient by saliva, effusion or blood be suppressed maximally. Japanese Patent Publication

No. 34325/1990 improves the technique of Japanese Patent Publication No. 12728/1989, and describes that a composition, which comprises a suitable combination of a water soluble polymer (e.g., hydroxyethylcellulose), a 5 certain type of methacrylate copolymer (e.g., aminoalkyl methacrylate copolymer RS), and a solubilizer therefor (e.g., triacetin) in addition to the combination of a magnesium compound (e.g., magnesium chloride (hexahydrate))-polyhydric alcohol (e.g., glycerin)-10 minocycline, resides at the site of administration for a long time, with a persistent effect, without impairing the stability of minocycline. Japanese Unexamined Patent Publication No. 89874/1995 describes a sustained release oral ointment characterized by containing a hydrophobic 15 ointment base (e.g., plastibase), a polyhydric alcohol (e.g., propylene glycol), an adhesive substance (e.g., hydroxypropyl methylcellulose), a metal compound containing aluminum as a constituent (e.g., aluminum hydroxide), and an active ingredient. This ointment can be administered to 20 a periodontal pocket, and is intended to increase the availability of the active ingredient while maintaining a sufficient concentration of the active ingredient at the lesion for a long period.

However, the development of a pharmaceutical 25 manufacturing technology for retaining the active ingredient at a topical site, such as a periodontal pocket, stably and for a long period has just begun to take shape, and the development of better techniques is demanded

strongly.

#### SUMMARY OF THE INVENTION

In view of these circumstances, the inventors of the present application have gained the idea that imparting  
5 post-application shape retention properties to a composition is necessary to release an active ingredient stably for a long period. Based on this idea, they conducted extensive studies on pharmaceutical manufacturing techniques, and developed a hardening preparation for  
10 topical administration, thereby accomplishing the present invention.

The present invention provides a pharmaceutical base, especially a pharmaceutical base for topical administration, typically a pharmaceutical base for  
15 intraoral administration, which has at least a surface portion thereof hardening at a topical site of application, thereby residing at the topical site for a long period, to enable the effect of an active ingredient to persist.

The present invention also provides a preparation  
20 for topical administration, especially a preparation for intraoral administration, which comprises an active ingredient incorporated into the above base, and which has at least a surface portion thereof hardening after application to a topical site, thereby enabling it to  
25 reside at the topical site for a long period, to enable the effect of an active ingredient to persist for a long period.

The present invention further provides an ointment for intraoral administration, which comprises an active

ingredient for treatment of periodontal diseases incorporated into the above base, and which is in a gel form for easy applicability before being applied to a periodontal pocket, but has at least a surface portion 5 thereof hardening after application, and resides in the periodontal pocket for a long period, thereby enabling the effect of the active ingredient to persist.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph showing the results of rheometric 10 measurement of bases of the present invention at the start (0 hours of immersion in purified water) of a test for evaluating how the bases of the present invention applied to a topical site changed in hardness (Example 2).

FIG. 2 is a graph showing the results of rheometric 15 measurement of the bases of the present invention immersed in purified water of 37°C for 24 hours in the test for evaluating how the bases of the present invention applied to the topical site changed in hardness (Example 2).

FIG. 3 is a graph showing the results of rheometric 20 measurement of the bases of the present invention immersed in purified water of 37°C for 48 hours in the test for evaluating how the bases of the present invention applied to the topical site changed in hardness (Example 2).

FIG. 4 is a photograph showing the results of 25 investigation of satisfactory residence of the bases of the present invention when the bases were placed in an agar gel (Example 3).

#### DETAILED DESCRIPTION OF THE INVENTION

The base of the present invention consists  
essentially of a water insoluble polymer, and a solvent  
capable of dissolving the water insoluble polymer and  
compatible with water, and optionally containing other  
5 additives.

This base normally takes a soft gel form, and can be  
easily applied to a topical site (e.g., a periodontal  
pocket) as a cream or an ointment by a finger, or through a  
tube, or by means of a specially designed injection  
10 instrument such as a syringe. The solvent compatible with  
water enables water, which exists around the topical site  
of application, to enter at least a surface portion of the  
base in accordance with the outflow of the solvent from the  
base. As a result of entry of water, the water insoluble  
15 polymer hardens at least in the surface portion of the base.  
The hardened base has elasticity in some cases. Since the  
base hardens, and in some cases has elasticity, the base  
retains its shape. Thus, the disadvantage that the applied  
base, and the active ingredient contained therein are  
20 flowed out by a physical force, such as that of water  
around the topical site, is prevented. Moreover, release  
of the active ingredient into the tissue can be controlled.

Examples of the water insoluble polymer used in the  
present invention are one or more polymers selected from  
25 the group consisting of aminoalkyl methacrylate copolymer  
RS, aminoalkyl methacrylate copolymer E, methacrylate  
copolymer L, methacrylate copolymer S, ethylcellulose,  
polyvinyl acetal diethylaminoacetate, hydroxypropyl

methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, carboxymethyl ethylcellulose, cellulose acetophthalate, rosin, sandarac, celluloid, shellac, and zein. However, these polymers are not restrictive, and a  
5 water insoluble polymer usable as a component to be added to the active ingredient can be suitably selected and used.

The water insoluble polymer in the base, or its amount incorporated is selected suitably so that when the polymer is dissolved in the solvent and combined with the  
10 solvent, a gelled material is formed. In consideration of viscosity and fluidity which affect handling during use or during production, the amount incorporated is typically about 5 to 40% by weight based on the entire composition, or preferably about 10 to 30% by weight if the mode of  
15 administration using a syringe is considered.

Examples of the solvent, which dissolves the water insoluble polymer and which is compatible with water, are one or more solvents selected from the group consisting of triethyl citrate, triacetin, tributyrin, diacetylethylene  
20 glycol, diethyl sebacate, diethyl phthalate, dibutyl phthalate, ethylene glycol, diethylene glycol, propylene glycol, dipropylene glycol, polyethylene glycol, glycerin, and acetyl glycerin fatty acid ester. However, these solvents are not restrictive, and a solvent usable as a  
25 component to be added to the active ingredient can be suitably selected and used.

The solvent in the base, and its amount incorporated are selected suitably so that when the solvent is combined

with the water insoluble polymer, a gelled material is formed. In consideration of viscosity and fluidity which affect handling during use or during production, the amount incorporated is typically about 30 to 95% by weight based  
5 on the entire composition, or preferably about 40 to 70% by weight if the mode of administration using a syringe is considered.

As the base of the present invention, other additives often used in the pharmaceutical manufacturing field may be  
10 incorporated. The type and amount of use of such additive can be determined, as desired, by a person of ordinary skill in the art. Examples of the additive are pH regulators for improving the stability of the active ingredient, and solubility of the active ingredient at  
15 the topical site (e.g., organic acids such as adipic acid and fumaric acid, inorganic acid salts such as phosphates, chelating agents such as disodium ethylenediaminetetraacetate); adhesives for improving residence in the tissue where the base is applied (e.g.,  
20 hydroxypropylcellulose, hydroxypropyl methylcellulose, methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, pullulan,  
carboxyvinylpolymer, sodium alginate, psyllium gum, gelatin, agar, carrageenan, and dextrin), swelling agents (e.g.,  
25 low-substituted hydroxypropylcellulose, calcium carboxymethylcellulose, carboxymethylcellulose, crosspovidon, starch, partially pregelatinized starch, and acrylic starch), fats and oils for controlling the rate of

PCT/EP2004/002565

hardening of the base and the release of the active ingredient by changing the leachability of the solvent from the base (e.g., paraffin, carnauba wax, rapeseed oil, olive oil, orange oil, eucalyptus oil, peanut oil, wheat germ oil, cacao butter, sesame oil, bleached beeswax, white petrolatum, and microcrystalline wax), fatty acids and their derivatives such as salts and esters (e.g., stearic acid, intermediate chain fatty acid triglyceride, hard fat, calcium stearate, aluminum stearate, and isopropyl myristate), surface active agents (e.g., sucrose ester of fatty acid, lauromacrogol, cetomacrogol, glyceryl monostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan trioleate, sorbitan sesquioleate, polyoxyethylene hydrogenated castor oil, and polyoxyl stearate), and polyhydric alcohols/higher alcohols (e.g., polyethylene glycol, propylene glycol, stearyl alcohol, and cetanol). In terms of the physical properties of the preparation and the release of the active ingredient, stearic acid and stearyl alcohol are particularly preferred. When a fat or an oil is incorporated as an additive, that having compatibility with the solvent used is preferred. A fat or oil which is solid at room temperature is dissolved, under heat, in the solvent, and cooled when used.

The amounts of the above-mentioned additives incorporated are suitably set from the aspects of physical properties and releasability required of the preparation or pharmaceutical base.

When the base of the present invention is used to

prepare a composition for intraoral administration, an insoluble or slightly soluble additive powder may be incorporated into the solvent in order to improve the properties, such as viscosity and stringiness, before 5 application to a topical site in the mouth. Its examples are polyethylene powder, hydrogenated vegetable oil powder, talc, magnesium stearate, sugar alcohol, anhydrous silicon dioxide, dibasic calcium phosphate, carnauba wax, kaolin, synthetic aluminum silicate, titanium oxide, calcium 10 carbonate, and bentonite. In terms of the physical properties of the preparation and the release of the active ingredient, polyethylene powder, hydrogenated vegetable oil powder, and carnauba wax are particularly preferred.

The additive powder insoluble in the solvent, or its 15 amount incorporated is suitably selected in order to improve handling during production, and the properties, such as viscosity and stringiness, before application to a topical site in the mouth. A typical amount incorporated is about 5 to 50% by weight based on the entire composition. 20 In terms of the dispersion stability in the composition, its specific gravity is preferably in the range of 0.5 to 1.5 relative to the solvent used, and its particle diameter is 100  $\mu\text{m}$  or less, preferably 10  $\mu\text{m}$  or less.

The present invention also provides a pharmaceutical 25 composition or an ointment for topical administration, which is produced by incorporating an active ingredient into the above base, and which takes a gel form or an ointment form before being applied to a topical site, but

has a surface portion thereof promptly hardening after application to the topical site, and resides in the topical site for a long period to release the active ingredient slowly in the topical site during this period.

- 5       The pharmaceutical composition for topical administration according to the present invention is not restricted in the range of application, and can be used topically in various fields, such as, ophthalmology (ocular mucous membrane), otorhinolaryngology (nasal cavity, oral cavity), dentistry (periodontal disease, dental caries, etc.), oral surgery (preoperative and postoperative measures, etc.), gynecology (vaginal cavity), digestive medicine (rectal cavity, etc.), urology, dermatology, and plastic surgery (wound surface, decubitus surface, etc.).
- 10      15     The pharmaceutical composition is also usable as a drug for animals in the same fields.

In the composition of the present invention, the amount of the active ingredient incorporated may be suitably selected in order to obtain the desired effect.

- 20      The suitable range is about 0.001 to about 30% by weight, more preferably about 0.01 to about 10% by weight, based on the entire base. The active ingredient can be made existent in a state dissolved, dispersed or suspended in the solvent. The active ingredient may be incorporated, as a solution in the selected solvent, into the base, or if not sufficiently soluble in the solvent, may be incorporated, as a fine powder or as a dispersion or suspension in the solvent, into the base. To suppress the
- 25

rate of release from the base or enhance the stability of  
the active ingredient, the active ingredient can be  
incorporated as a fine powder, dispersion or suspension,  
depending on the method of production or the method of  
5 application.

Moreover, if the bulk drug, which is in a crystal or  
a crystalline powder form, is used, the quality of the  
resulting composition may be nonuniform as a whole, when  
the bulk drug is only dispersed in the base directly. In  
10 this case, the bulk drug may be ground to a small particle  
size, or dissolved in a certain solvent, before being  
kneaded with the base, during the production process.

If the bulk drug is used in ground form, the particle  
diameter of the active ingredient is not limited. However,  
15 it is preferably about 1  $\mu\text{m}$  to about 500  $\mu\text{m}$ , more  
preferably about 10  $\mu\text{m}$  to about 200  $\mu\text{m}$ , from the aspect of  
handling during the production process.

The active ingredient may be pretreated before  
incorporation, if this is necessary to control the rate of  
20 release into tissue and improve its stability. Examples of  
the pretreatment are coating, microcapsulation, adsorption  
to a porous substance, and adsorption to an ion exchange  
resin. These techniques are well known in the field of  
pharmaceutical manufacturing techniques.

25 The pharmaceutical composition for topical  
administration according to the present invention can be  
used as antibiotics, antibacterials, antimycotics,  
antivirals, bactericides, anti-inflammatories, local

PCT/EP2009/062350

anesthetics, vasoconstrictors, steroid hormones,  
antihistaminics, prostaglandins, or antispasmodics. Active  
ingredients which can be incorporated into them are not  
restricted. Examples of the active ingredient include  
5 antibiotics, for example,  $\beta$ -lactams such as ampicillin,  
aminoglycosides such as kanamycin sulfate, tetracyclines  
such as tetracycline hydrochloride and minocycline,  
polypeptides such as polymyxin B sulfate, macrolides such  
as clarithromycin, and chloramphenicols such as  
10 chloramphenicol. As the antibacterial, a new quinolone  
such as tosufloxacin tosilate, or a synthetic antibacterial  
such as combination of sulfamethoxazole-trimethoprim is  
incorporated. As the antimycotic, a polyene macrolide such  
as amphotericin or an azole and the like is incorporated.  
15 As the antiviral, aciclovir or vidarabine is incorporated.  
As the bactericide, cetylpyridinium chloride or povidone  
iodine is incorporated. As the anti-inflammatory,  
glycyrrhizinate dipotassium or lysozyme hydrochloride is  
incorporated. As the local anesthetic, lidocaine or  
20 dibucaine hydrochloride is incorporated. As the  
vasoconstrictor, naphazoline hydrochloride or dl-  
methylephedrine hydrochloride is incorporated. As the  
steroid hormone, hydrocortisone butyrate is incorporated.  
As the antihistaminic, diphenhydramine hydrochloride or  
25 chlorpheniramine maleate is incorporated. As the  
prostaglandin, dinoprost or dinoprostone is incorporated.  
As the antispasmodic, crotamiton is incorporated.

Each of the compositions can be used, alone or as a

combination of two or more, for treatment or prophylaxis of diseases in various fields, such as ophthalmology, otorhinolaryngology, dentistry, oral surgery, gynecology, digestive medicine, dermatology, urology, and plastic 5 surgery.

An intraoral preparation, in particular, is one of the preferred embodiments of the present invention. Penem compounds are non-natural type  $\beta$ -lactam compounds designed based on the idea of fusing the structures of penicillin 10 and cephalosporin (e.g., Woodward, R.B., In Recent Advances in the Chemistry of  $\beta$ -Lactam Antibiotics; Elks, J., Ed; The Chemical Society; London, 1977; Spec. No. 28, p. 167-180, and Japanese Unexamined Patent Publication Nos. 207387/86, 162694/88, 222486/85, and 119486/79). These compounds are 15 antibiotics of a new type having the broad antibacterial spectrum and high safety of penicillin antibiotics and cephem antibiotics which are  $\beta$ -lactam antibiotics, and the potent antibacterial activity and high stability to  $\beta$ -lactamase of carbapenem antibiotics. Currently, a 20 2.5hydrate of sodium (+)-(5R,6S)-6-[(R)-1-hydroxyethyl]-7-oxo-3-[(R)-2-tetrahydrofuryl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (faropenem sodim, hereinafter referred to as Compound 1) is used as an oral drug for treatment of various infectious diseases. Because 25 of the novel skeleton, penem ring, this compound is reported to exhibit potent antibacterial activity against Gram-positive bacteria, including not only methicillin sensitive *Staphylococcus aureus* (MSSA), *Streptococcus*

pyogenes, and Streptococcus pneumoniae, but also penicillin resistant Streptococcus pneumoniae (PRSP), oral streptococci, and enterococci against which conventional  $\beta$ -lactam antibiotics have not been fully effective, and is  
5 also reported to show a wide antibacterial spectrum covering Gram-negative bacteria such as Haemophilus influenzae and anaerobic bacteria such as Bacteroides species (Antibiotics & Chemotherapy, Vol. 13, No. 10, p. 74-80, 1997). It is also reported to have potent  
10 antibacterial activity against pathogens of periodontitis, including Porphyromonas gingivalis (CHEMOTHERAPY, Vol. 42, S-1, p. 38-50, 1994), as well as species from odontogenic infection which have become noticeably resistant to antibiotics in recent years (Chemotherapy, Vol. 45, No. 11, p. 965-971, 1997).

Generally, penem compounds are chemically very unstable substances against hydrolysis, oxidation or optical isomerization, as are other  $\beta$ -lactam compounds. Thus, it is difficult to produce a pharmaceutical  
20 composition for topical administration, the pharmaceutical composition locally utilizing the excellent efficacy of these compounds against inflammatory diseases, pyogenic diseases, and diseases due to infection with resistant strains. However, the base of the present invention, which  
25 consists essentially of a water insoluble polymer and a solvent capable of dissolving the water insoluble polymer and compatible with water, has been found to be capable of maintaining a penem compound as suspended or dispersed

particles stably for a long period.

The pharmaceutical composition for topical administration according to the present invention is in the form of an ointment or a gel before topical application,

5 and can be administered using a syringe or the like. After administration, this preparation forms a water insoluble film in its surface portion in accordance with leaching of the solvent contained and/or absorption of water. In the meantime, the entire preparation hardens and retains its  
10 shape, thus residing at the topical site for a long period.

The duration of residence can be designed to last for several weeks. Hence, the composition of the present invention is also suitable for designing a sustained release preparation which slowly releases an active

15 ingredient incorporated to maintain the concentration of the active ingredient at a topical site for a long period.

#### Examples

The present invention will now be described more concretely by way of the following examples, which in no  
20 way limit the scope of the invention.

#### Example 1

The following bases and preparations were prepared. The formulations of the respective compositions are shown in Tables 1, 2, 4, 5 and 7.

25 Base Example 1

Aminoalkyl methacrylate copolymer RS (trade name: Eudoragit RS, Röhm, Federal Republic of Germany) was dissolved in triethyl citrate with heating at 90°C, and

allowed to cool to room temperature. Then, the mixture was defoamed under reduced pressure to obtain a composition.

Base Examples 2 to 4

Aminoalkyl methacrylate copolymer RS was dissolved in  
5 triethyl citrate with heating at 90°C, and allowed to cool to room temperature. Then, polyethylene powder was added, and uniformly mixed. The resulting mixture was defoamed under reduced pressure to obtain a composition.

Base Example 5

10 Aminoalkyl methacrylate copolymer RS was dissolved in triethyl citrate with heating at 90°C, and allowed to cool to room temperature. Then, Food Blue No. 1 was added, and uniformly mixed. The resulting mixture was defoamed under reduced pressure to obtain a composition.

15 Base Example 6

Aminoalkyl methacrylate copolymer RS was dissolved in triethyl citrate with heating at 90°C, and allowed to cool to room temperature. Then, Food Blue No. 1 and polyethylene powder were added, and uniformly mixed. The  
20 resulting mixture was defoamed under reduced pressure to obtain a composition.

Base Example 7

Ethylcellulose was dissolved in triethyl citrate with heating at 90°C, and while the solution was hot, stearyl  
25 alcohol was added, and mixed uniformly. The mixture was allowed to cool to room temperature, whereafter Food Blue No. 1 was added, and uniformly mixed. The resulting mixture was defoamed under reduced pressure to obtain a

composition.

Comparative Base Example 1

Hydroxyethylcellulose and magnesium chloride (hexahydrate) were dispersed in glycerin, and heated at 5 100°C until dissolved. After dissolution, the solution was cooled to 50°C to obtain a mixture. Separately, a solution of aminoalkyl methacrylate copolymer RS in triacetin was prepared. This solution was added to the mixture, and the system was uniformly mixed to obtain a composition.

10 Comparative Base Example 2

Plastibase, aluminum hydroxide, propylene glycol, and hydroxypropyl methylcellulose were uniformly mixed to obtain a composition.

Comparative Base Example 3

15 The formulation of this example contained Comparative Base Example 1 and a suitable amount of Food Blue No. 1 added thereto. That is, hydroxyethylcellulose and magnesium chloride (hexahydrate) were dispersed in glycerin, and heated at 100°C until dissolved. After dissolution, 20 the solution was cooled to 50°C to obtain a mixture. Separately, a solution of aminoalkyl methacrylate copolymer RS in triacetin was prepared. This solution and Food Blue No. 1 were added to the mixture, and the system was uniformly mixed to obtain a composition.

25 Comparative Base Example 4

The formulation of this example contained Comparative Base Example 2 and a suitable amount of Food Blue No. 1 added thereto. That is, plastibase, aluminum hydroxide,

propylene glycol, hydroxypropyl methylcellulose, and Food Blue No. 1 were uniformly mixed to obtain a composition.

### Preparation Example 1

Aminoalkyl methacrylate copolymer RS was dissolved  
5 in triethyl citrate with heating at 90°C, and allowed to  
cool to room temperature. Then, minocycline hydrochloride  
and polyethylene powder were added, and the system was  
uniformly mixed. The resulting mixture was defoamed under  
reduced pressure to obtain a composition. The minocycline  
10 hydrochloride was that which passed through Japanese  
Pharmacopoeia Standard Sieve No. 100 and remained on JP  
Standard Sieve No. 200.

### Comparative Preparation Example 1

Hydroxyethylcellulose and magnesium chloride  
15 (hexahydrate) were dispersed in glycerin, and heated at  
100°C until dissolved. After dissolution, the solution  
was cooled to 50°C, whereafter minocycline hydrochloride  
was added and uniformly dissolved to obtain a mixture.  
Separately, a solution of aminoalkyl methacrylate copolymer  
20 RS in triacetin was prepared. This solution was added to  
the mixture, and the system was uniformly mixed to obtain a  
composition.

### Preparation Example 2

Aminoalkyl methacrylate copolymer RS was dissolved in triethyl citrate with heating at 90°C, and allowed to cool to room temperature. Then, faropenem sodium and polyethylene powder were added, and the system was uniformly mixed. The resulting mixture was defoamed under

reduced pressure to obtain a composition. The faropenem sodium was that which passed through JP Standard Sieve No. 100 and remained on JP Standard Sieve No. 200.

Preparation Example 3

5       Ethylcellulose was dissolved in triethyl citrate with heating at 90°C, and allowed to cool to room temperature. Then, faropenem sodium and polyethylene powder were added, and the system was uniformly mixed. The resulting mixture was defoamed under reduced pressure to obtain a composition.

10      The faropenem sodium was that which passed through JP Standard Sieve No. 100 and remained on JP Standard Sieve No. 200.

Preparation Example 4

15      Aminoalkyl methacrylate copolymer RS and ethylcellulose were dissolved in triethyl citrate with heating at 90°C, and allowed to cool to room temperature. Then, faropenem sodium and polyethylene powder were added, and the system was uniformly mixed. The resulting mixture was defoamed under reduced pressure to obtain a composition.

20      The faropenem sodium was that which passed through JP Standard Sieve No. 100 and remained on JP Standard Sieve No. 200.

Preparation Example 5

25      Aminoalkyl methacrylate copolymer RS was dissolved in triacetin with heating at 90°C, and allowed to cool to room temperature. Then, faropenem sodium and polyethylene powder were added, and the system was uniformly mixed. The resulting mixture was defoamed under reduced pressure to

obtain a composition. The faropenem sodium was that which passed through JP Standard Sieve No. 100 and remained on JP Standard Sieve No. 200.

Preparation Example 6

5       Ethylcellulose was dissolved in triethyl citrate with heating at 90°C, and while the solution was hot, stearic acid was added, followed by mixing the system uniformly. After the mixture was allowed to cool to room temperature, faropenem sodium was added, and the system was uniformly  
10 mixed. The resulting mixture was defoamed under reduced pressure to obtain a composition. The faropenem sodium was that which passed through JP Standard Sieve No. 100 and remained on JP Standard Sieve No. 200.

Preparation Example 7

15       Ethylcellulose was dissolved in triethyl citrate with heating at 90°C, and while the solution was hot, stearyl alcohol was added, followed by mixing the system uniformly. After the mixture was allowed to cool to room temperature, faropenem sodium was added, and the system was uniformly  
20 mixed. The resulting mixture was defoamed under reduced pressure to obtain a composition. The faropenem sodium was that which passed through JP Standard Sieve No. 100 and remained on JP Standard Sieve No. 200.

Example 2   Evaluation of shape retention of the  
25 preparation (needle penetration test)

To ensure residence at the site of administration, the base of the present invention is characterized by hardening over time in accordance with the outflow of the

solvent and entry of water after administration. Changes in the hardness of the base applied topically were evaluated by a rheometer using a model.

Concretely, each of the bases was filled into a cylindrical pocket of 10.0 mm in diameter and 5.0 mm in depth, and allowed to stand in purified water of 37°C. At the start of the test (0 hours), at 24 hours, and at 48 hours, the base was penetrated with a plunger as a needle (needle front end diameter: 4.0 mm) inserted at a rate of 20 mm/min with the use of a rheometer (NRM-3002D, Fudo Kogyo) to measure stress with the passage of time. The formulations of the bases used in the test are shown in Tables 1 and 2.

During penetration at the constant rate, the point of inflection is observed in stress when the base is broken, provided that the base has hardened. The stress at this time of breakage is designated as maximum elastic stress (g), and the distance over which the needle was penetrated is designated as elastic limiting distance (mm). The results are shown in Table 3 and FIGS. 1 to 3.

With Comparative Base Examples 1 and 2, no points of inflection were observed at any of 0, 24 and 48 hours, thus demonstrating that none of these bases hardened. With Base Examples 1, 2, 3 and 4 of the present invention, no points of inflection were observed at 0 hours, but at 24 hours, points of inflection were noted for the needle penetration distance of 1.2 to 2.1 mm. Thus, Base Examples 1, 2, 3 and 4 of the present invention showed the properties of

hardening and retaining their shapes during storage in purified water. Also, depending on the amount of the water insoluble polymer incorporated, or the amount of incorporation of the solvent capable of dissolving the 5 water insoluble polymer and compatible with water, the resulting compositions were found to be different in the degree of hardening.

In Base Examples 3 and 4, in particular, the maximum elastic stress and the distance to the point of inflection 10 (elastic limiting distance) at 48 hours were comparable to those at 24 hours. Thus, the present invention was demonstrated to be capable of designing a composition whose properties are kept nearly constant after a lapse of a certain time.

15

Table 1

Ingredient	Base Ex. 1	Base Ex. 2	Base Ex. 3	Base Ex. 4
Eudragit RS	35	6	13	20
Triethyl citrate	65	54	51	47
Polyethylene powder		40	36	33
Total	100	100	100	100

(unit: %)

Table 2

Ingredient	Comp. Base Ex. 1	Comp. Base Ex. 2
Eudoragit RS	2.06	
Hydroxyethylcellulose	4.12	
Magnesium chloride hexahydrate	5.15	
Glycerin	76.30	
Triacetin	12.37	
Plastibase		79.89
Aluminum hydroxide		2.76
Propylene glycol		2.04
Hydroxypropylmethylcellulose		15.31
Total	100	100

(unit: %)

Table 3 Results of Measurement

Time		Base Ex. of present invention				Comp. Base Ex.	
		1	2	3	4	1	2
0 hrs	Maximum elastic stress (g)	NPI	NPI	NPI	NPI	NPI	NPI
	Elastic limiting distance (mm)		-	-	-	-	-
24 hrs	Maximum elastic stress (g)	16	28	33	82	NPI	NPI
	Elastic limiting distance (mm)	1.5	1.2	1.4	2.1	-	-
48 hrs	Maximum elastic stress (g)	13	15	29	80	NPI	NPI
	Elastic limiting distance (mm)	1.4	1.3	1.2	2.0	-	-

NPI: No point of inflection

Example 3 Evaluation of shape retention of base

When applied to a topical site, such as a periodontal pocket, the base of the present invention has at least a surface portion thereof hardening, and can thus maintain 5 its shape, as initially applied, for a long period. To confirm this feature, the following test was conducted:

A 2% agar gel having a slit of 10 mm in width and 20 mm in depth was used as a model of a periodontal pocket. A front end of a plastic piece measuring 5 mm in width, 30 mm 10 in length, and 0.02 mm in thickness was coated with about 10 mg of each preparation, and the plastic piece was inserted into the slit of 10 mm in width and 20 mm in depth provided in the 2% agar gel. The agar gel was stored in an incubator at 37°C, and allowed to stand therein for a 15 certain time. Then, the plastic piece was taken out, and the shape retention of the base incorporating a food color instead of an active ingredient was checked. The formulations of the bases used in the test are shown in Table 4.

As shown in FIG. 4, all of Base Examples 5, 6 and 7 of the present invention nearly retained the initial shape until 48 hours later. On the other hand, Comparative Base Example 3 lost about a half of the initial shape at 6 hours, and lost almost all of the initial shape at 24 hours. 25 Comparative Base Example 4 lost about a half of the initial shape at 1 hour, and lost almost all of the initial shape at 6 hours. Hence, the base of the present invention proved to be excellent in shape retention, and satisfactory

in topical residence.

Table 4

Ingredient	Base Ex. 5	Base Ex. 6	Base Ex. 7	Comp. Base Ex. 3	Comp. Base Ex. 4
Food Blue No. 1	0.20	0.20	0.20	0.20	0.20
Ethylcellulose	-	-	16.29	-	-
Eudoragit RS	34.93	26.48	-	2.06	-
Triethyl citrate	64.87	49.90	63.14	-	-
Polyethylene powder	-	23.42	-	-	-
Stearyl alcohol	-	-	20.37	-	-
Hydroxyethyl-cellulose	-	-	-	4.12	-
Magnesium chloride hexahydrate	-	-	-	5.14	-
Triacetin	-	-	-	12.35	-
Glycerin	-	-	-	76.13	-
Plastibase	-	-	-	-	79.73
Aluminum hydroxide	-	-	-	-	2.75
Propylene glycol	-	-	-	-	2.04
Hydroxypropyl methylcellulose	-	-	-	-	15.28
Total	100.00	100.00	100.00	100.00	100.00

(unit: %)

Example 4 Confirmation (in vitro) of drug release rate

5 The rate of drug release from the preparation of each of Preparation Examples 1 to 7 was confirmed in vitro. To examine the release rate of the drug at the site of

administration, a test was conducted using a model of a periodontal pocket. Concretely, the composition filled into a syringe having a front end internal diameter of 300 µm was accurately weighed in an amount of about 10 mg, and  
5 coated in a nearly circular form onto a front end of a plastic piece measuring 5 mm in width, 30 mm in length, and 0.02 mm in thickness. The plastic piece was inserted into a slit of 10 mm in width and 20 mm in depth provided in a 2% agar gel. The agar gel was stored in an incubator at  
10 37°C, and the plastic piece was taken out after a lapse of a certain time. Then, the drug remaining in the preparation was quantitatively determined.

Conditions for analysis of faropenem sodium: A high performance liquid chromatographic column of stainless steel packed with octadecylsilylated silica gel was used.  
15 The column temperature was set at 40°C. As a mobile phase, a mixture of water, acetonitrile and a 1 mol/l aqueous solution of phosphoric acid (200 ml:900 ml:10 ml) incorporating 3.1 g of sodium dihydrogenphosphate was used.  
The flow rate was adjusted so that the retention time of  
20 faropenem sodium would be about 14 minutes. An ultraviolet absorption spectrophotometer was used as a detector, and a measurement wavelength of 305 nm was used.

Conditions for analysis of minocycline hydrochloride:  
25 A high performance liquid chromatographic column of stainless steel packed with octadecylsilylated silica gel was used. The column temperature was set at 40°C. The mobile phase used was a solution of 20.2 g of triethylamine

in a mixture of water and acetonitrile (100 ml:50 ml), the solution being adjusted to pH 2.2 with the addition of phosphoric acid. The flow rate was adjusted so that the retention time of minocycline hydrochloride would be about 5 14 minutes. An ultraviolet absorption spectrophotometer was used as a detector, and a measurement wavelength of 354 nm was used.

The formulations of the preparations used in the analyses are shown in Tables 5 and 7. The corresponding 10 results of analyses are shown in Tables 6 and 8.

A comparison between Preparation Example 1 and Comparative Preparation Example 1 using minocycline hydrochloride as the active ingredient showed that Preparation Example 1 with satisfactory shape retention of 15 the preparation had a large residual amount of the active ingredient residing at the topical site of administration. The results on Preparation Examples 2 to 7 using faropenem sodium as the active ingredient showed that the release rate of the active ingredient could be controlled 20 arbitrarily, depending on the differences in the types and/or amounts of incorporation of the water insoluble polymer, the solvent capable of dissolving the water insoluble polymer and compatible with water, and other additives.

Table 5 Formulations of Preparation Example 1 and Comparative Preparation Example 1

Ingredient	Preparation Ex. 1	Comp. Preparation Ex. 1
Minocycline hydrochloride	2	2
Aminoalkyl methacrylate copolymer RS	26	2
Triethyl citrate	49	
Polyethylene powder	23	
Hydroxyethylcellulose		4
Magnesium chloride·hexahydrate		5
Glycerin		75
Triacetin		12
Total	100	100

(unit: %)

5 Table 6 Residual Amount (%) of Minocycline Hydrochloride in Preparation

Time	Preparation Ex. 1	Comp. Preparation Ex. 1
2 hr	94.3	47.1
18 hr	28.8	4.4

Table 7 Formulations of Preparation Examples 2 to 7

Ingredient	Pre. Ex.2	Pre. Ex.3	Pre. Ex.4	Pre. Ex.5	Pre. Ex.6	Pre. Ex.7
Faropenem sodium	2	2	2	2	2	2
Ethylcellulose		14	7		16	16
Aminoalkyl methacrylate copolymer RS	26		13	26		
Triethyl citrate	49	54	52		62	62
Triacetin				49		
Polyethylene powder	23	30	26	23		
Stearic acid					20	
Stearyl alcohol						20
Total	100	100	100	100	100	100

(unit: %)

Table 8 Residual Amount (%) of Faropenem Sodium in Preparation

Time	Prep. Ex.2	Prep. Ex.3	Prep. Ex.4	Prep. Ex.5	Prep. Ex.6	Prep. Ex.7
2 hr	48.9	97.2	59.2	34.2	89.8	91.7
18 hr	6.9	9.3	8.1	5.5	26.5	43.3

5

CLAIMS

1. A pharmaceutical composition for topical administration, comprising an active ingredient, a water insoluble polymer, and a solvent capable of dissolving the water insoluble polymer and compatible with water, and optionally containing other additive.
2. The pharmaceutical composition for topical administration as claimed in claim 1, which is an antibiotic, an antibacterial, an antimycotic, an antiviral, a bactericide, an anti-inflammatory, a local anesthetic, a vasoconstrictor, a steroid hormone, an antihistaminic, a prostaglandin, or an antispasmodic in an animal including human.
3. The pharmaceutical composition for topical administration as claimed in any one of claims 1 to 2, which is used for intraoral administration.
4. The pharmaceutical composition for topical administration as claimed in any one of claims 1 to 3, wherein the water insoluble polymer is one or more polymers selected from the group consisting of aminoalkyl methacrylate copolymer RS, aminoalkyl methacrylate copolymer E, methacrylate copolymer L, methacrylate copolymer S, ethylcellulose, polyvinyl acetal diethylaminoacetate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, carboxymethyl ethylcellulose, cellulose acetophthalate, rosin, sandarac, celluloid, shellac, and zein.
5. The pharmaceutical composition for topical

administration as claimed in any one of claims 1 to 4,  
wherein the solvent capable of dissolving the water  
insoluble polymer and compatible with water is one or more  
solvents selected from the group consisting of triethyl  
citrate, triacetin, tributyrin, diacetylene glycol,  
diethyl sebacate, diethyl phthalate, dibutyl phthalate,  
ethylene glycol, diethylene glycol, propylene glycol,  
dipropylene glycol, polyethylene glycol, glycerin, and  
acetyl glycerin fatty acid ester.

6. The pharmaceutical composition for topical  
administration as claimed in any one of claims 1 to 5,  
wherein an additive powder insoluble or slightly soluble in  
the solvent is incorporated as the other additive.

7. The pharmaceutical composition for topical  
administration as claimed in any one of claims 1 to 5,  
wherein a pH adjustor is incorporated as the other additive.

8. The pharmaceutical composition for topical  
administration as claimed in any one of claims 1 to 5,  
wherein an adhesive and/or a swelling agent are or is  
incorporated as the other additive.

9. The pharmaceutical composition for topical  
administration as claimed in any one of claims 1 to 5,  
wherein one or more additives selected from the group  
consisting of fats and oils, fatty acids and fatty acid  
derivatives such as salts or esters of the fatty acids,  
surface active agents, polyhydric alcohols, and higher  
alcohols are incorporated as the other additives.

10. The pharmaceutical composition for topical

administration as claimed in any one of claims 1 to 9,  
which is a sustained release preparation.

11. The pharmaceutical composition for topical  
administration as claimed in claim 10, wherein the active  
ingredient is a penem antibiotic.

12. A pharmaceutical base comprising a water insoluble  
polymer, and a solvent capable of dissolving the water  
insoluble polymer and compatible with water, and optionally  
containing additive.

13. The pharmaceutical base of claim 12, which is used in  
a pharmaceutical composition for topical administration.

14. Use of a water insoluble polymer for production of a  
pharmaceutical composition for topical administration by  
mixing with a solvent capable of dissolving the water  
insoluble polymer and compatible with water.

15. Use of a solvent for production of a pharmaceutical  
composition for topical administration by mixing with a  
water insoluble polymer, the solvent capable of dissolving  
the water insoluble polymer and compatible with water.

16. An agent for treatment of periodontal disease,  
comprising an active ingredient for treatment of  
periodontal disease, a water insoluble polymer, and a  
solvent capable of dissolving the water insoluble polymer  
and compatible with water, and optionally other additive.

ABSTRACT

A pharmaceutical composition for topical administration, which resides at a topical site of application for a long period and can control the release 5 rate of an active agent, is provided. The present invention is a pharmaceutical composition for topical administration comprising an active ingredient, a water insoluble polymer, and a solvent capable dissolving the water insoluble polymer and compatible with water, and 10 optionally containing other additive.


09/786815

FIG. 1


Needle Penetration Test by Rheometer

Immersion time 0 hrs


Base Ex. 1




Base Ex. 2



Base Ex. 3




Base Ex. 4




Comp.

Base Ex. 1



Comp.

Base Ex. 2




09/786815

FIG. 2

Needle Penetration Test by Rheometer


Immersion time 24 hrs



*FIG. 3*


Needle Penetration Test by Rheometer

Immersion time 48 hrs



09/786815

FIG. 4



Case No. \_\_\_\_\_

Nixon & Vanderhye P.C. (12/97)

RULE 63 (37 C.F.R. 1.63)  
DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION

the specification of which (check applicable box(s)):

is attached hereto

was filed on \_\_\_\_\_

as U.S. Application Serial No. \_\_\_\_\_

was filed as PCT International application No. PCT/JP00/04651 on July 12, 2000

and (if applicable to U.S. or PCT application) was amended on \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number	Country	Day/Month/Year Filed
198012/1999	Japan	12/7/99

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

Application Number	Date/Month/Year Filed
--------------------	-----------------------

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior applications and the national or PCT international filing date of this application:

Prior U.S./PCT Application(s):	Status: patented	
Application Serial No.	Day/Month/Year Filed	Status: pending, abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And I hereby appoint NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8<sup>th</sup> Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27076; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Basha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 92106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffry H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr. 29366; Thomas E. Byrne, 32205; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; William J. Griffin, 31260; Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Berquist, 34776; Updeep S. Gill, 37334.

100 Inventor's Signature: Mitsutoshi Date: May 18, 2001  
Inventor: Mitsutoshi MI TATARA Japanese  
(first) (last) (citizenship)

Residence: (city) Kanagawa (state/country) Japan J  
Post Office Address: 221-19, Setogaya-cho, Hodogaya-ku, Yokohama-shi,  
(Zip Code) Kanagawa 240-0024 Japan

200 Inventor's Signature: Toshihito Date: May 18, 2001  
Inventor: Toshihito MI SHIMIZU Japanese  
(first) (last) (citizenship)

Residence: (city) Tokyo (state/country) Japan JPK  
Post Office Address: 2-25, Nishiarai-honmachi 5-chome, Adachi-Ku,  
(Zip Code) Tokyo, 123-0845 Japan

300 Inventor's Signature: Ryoichi Date: May 18, 2001  
Inventor: Ryoichi MI FUKUMOTO Japanese  
(first) (last) (citizenship)

Residence: (city) Tokyo (state/country) Japan JPK  
Post Office Address: 251-4, Dairakuji-machi, Hachioji-shi,  
(Zip Code) Tokyo 193-0816 Japan

FOR ADDITIONAL INVENTORS, check box  and attach sheet with same information and signature and date for each.

**RULE 63 (37 C.F.R. 1.63)**  
**DECLARATION AND POWER OF ATTORNEY**  
**FOR PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

*400*

4.	Inventor's Signature:	<i>Masaaki Nomura</i>			Date: May 18, 2001
	Inventor:	Masaaki	MI	NOMURA	(citizenship) Japanese
	Residence: (city)	(first) Gunma	(state/country)	Japan	(Zip Code)
	Post Office Address:	668-7, Nissato, Meiwa-machi, Ohra-gun, Gunma 370-0708 Japan			
5.	Inventor's Signature:				Date: _____
	Inventor:		MI	(last)	(citizenship) _____
	Residence: (city)	(first)	(state/country)		
	Post Office Address:				
	(Zip Code)				
6.	Inventor's Signature:				Date: _____
	Inventor:		MI	(last)	(citizenship) _____
	Residence: (city)	(first)	(state/country)		
	Post Office Address:				
	(Zip Code)				
7.	Inventor's Signature:				Date: _____
	Inventor:		MI	(last)	(citizenship) _____
	Residence: (city)	(first)	(state/country)		
	Post Office Address:				
	(Zip Code)				
8.	Inventor's Signature:				Date: _____
	Inventor:		MI	(last)	(citizenship) _____
	Residence: (city)	(first)	(state/country)		
	Post Office Address:				
	(Zip Code)				
9.	Inventor's Signature:				Date: _____
	Inventor:		MI	(last)	(citizenship) _____
	Residence: (city)	(first)	(state/country)		
	Post Office Address:				
	(Zip Code)				
10.	Inventor's Signature:				Date: _____
	Inventor:		MI	(last)	(citizenship) _____
	Residence: (city)	(first)	(state/country)		
	Post Office Address:				
	(Zip Code)				
11.	Inventor's Signature:				Date: _____
	Inventor:		MI	(last)	(citizenship) _____
	Residence: (city)	(first)	(state/country)		
	Post Office Address:				
	(Zip Code)				
12.	Inventor's Signature:				Date: _____
	Inventor:		MI	(last)	(citizenship) _____
	Residence: (city)	(first)	(state/country)		
	Post Office Address:				
	(Zip Code)				